Hepion Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Apr 16, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 16, 2024
HEPA$0.07-17.7%Stored close · as of Jul 8, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| Year EndedDecember 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Revenues | $— | $— |
| Costs and expenses: | ||
| Research and development | 35,639,656 | 33,269,337 |
| General and administrative | 9,618,298 | 10,348,465 |
| Asset impairment loss | 3,190,000 | 1,870,924 |
| Total operating expenses | 48,447,954 | 45,488,726 |
| Loss from operations | (48,447,954) | (45,488,726) |
| Other income (expense): | ||
| Interest expense | (9,465) | (10,164) |
| Change in fair value of contingent consideration and derivative financial instruments | (877,645) | 414,992 |
| Loss before income taxes | (49,335,064) | (45,083,898) |
| Income tax benefit (expense) | 409,022 | 2,883,849 |
| Net loss | (48,926,042) | (42,200,049) |
| Deemed dividend (see Note 4) | — | (3,137,500) |
| Net loss attributable to common shareholders | $(48,926,042) | $(45,337,549) |
| Weighted average common shares outstanding: | ||
| Basic and diluted | 3,970,810 | 3,811,472 |
| Net loss per common share: (see Note 11) | ||
| Basic and diluted | $(12.32) | $(11.90) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.